High-Throughput, Dual-Stream UHPLC/MS/MS Bioanalysis and Data-Deconvolution for Rapid Drug Discovery Applications

62nd ASMS Conference on Mass Spectrometry and Allied Topics, Baltimore MD 16-June-2014

> Brendon Kapinos Pfizer



HDO Group (Hit Discovery and Optimization)


ADME Screening (96- and 384-well assays) -Metabolism -DDI & Toxicity -Disposition -Permeability & Transporters

In Vitro Bioanalysis

- Transporter Studies
- Enzymology

Technology Development and Validation

Our Bioanalytical Work Spans a Broad Scope








Dual-arm (dual-stream) liquidhandler-type LC/MS/MS autosampler


High-throughput, large deck capacity, rapid sample analysis and *flexibility*

4 injection ports per arm, 4 front diverter valves allow multitude of LC modes and/or chemistries, functionalities











Our Bioanalytical Work Spans a Broad Scope




Case Study: Transporter Assay Bioanalysis

Challenge	Details
High sample burden	~1200 samples/week (32 compounds x 3 replicates x 6 plates x 2 studies)
Cassetted approach	4 compounds/sample (analyte, inhibitor, internal standard, assay control) different polarities, response, LC conditions, requires separation
Diversity of analytes	Ionization efficiency varies
Co-dosed inhibitors	Extremely high concentrations (10-100 $\mu\text{M})$
Membrane control	Atenolol: small, polar, extreme difference in response across plates
Rapid turnaround	Traditional gradient HPLC: 2min/injection (previously 20 hour run-time)

Compound-Dependent Ionization Efficiency



Compound-Dependent Ionization Efficiency





0.1µM verapamil (blue) and propranolol (red); co-elution in trap-and-elute mode


Co-elution may lead to suppression of poorly-ionizing compounds such


Propranolol signal suppressed ~20% by good ionizers such as verapamil at 5µM


10












Higher-Throughput Gradient Separation Via Dual-Stream UHPLC


Sample N	lame	Sample	Sample Type	Actual Concentration	Component Name	Retention Time	Acea	IS Retentio Time	IS Area	Area Ratio	Used	Calculated	Accurace	*Compound	Accuracy	
Group001. Ini			Elank	N/A	455.4 / 165.2	0.49	1252	NA	NG	NA		<0	NA	verapami	N/A	1
Group001, In	njection 3	3	Blank	N/A	455.4 / 165.2	0.71	1631	NA	NA	NA		<0	NA	verapamil	NUA	۰,
Group001, Inj	njection 4	4	Elenk	N/A	455.4 / 165.2	0.95	614	NA	NGA	NA		<0	NA	verapamil	N/A	
Group001, In			Blank	N/A		1.16	601	NA		NA		<0	NA	erapamil	N/A	,
Group001, In			Blenk	N/A		1,41	386	NA		NA		<0	NA	terapamil		
Group001, In			Standard	48.80		1.61	8548	NA		NA		47.379	97.09	verapamil	N/A	1
Group001, In			Standard	97.66 195.31	455.4 / 165.2 455.4 / 165.2	1.84	15682	NA		NA		96.915 209.588	99.24 107.31	verapamil	N/A	+
Group001, In Group001, In			Standard Standard	390.63		2.06	31908	NA		NA	4	425,218	107.31	v rapamil v rapamil	N/A	1
Group001, In			Standard	781.25		2.51	120161	NA		NA	R	822.397	105.00	vrapami	97.09	
Group001, In			Standard	1562.50		2.74	234527	NA		NA	R	1616.527	103.46	vracami		
Group001, In			Standard	3125.00		2.96	450109	NA		NA		3113.490	99.63	versemil	99.24	1
Group001, In			Standard	6250.00		3.19	879638	NA		NA	1	6089.093	97.43	verapamil	107.01	+
Group001, In			Standard	12500.00	455.4 / 165.2	3.41	1654847	NA	NA	NA	R	11478.915	91.83	erapamil	107.31	1
Group001, In	njection 16	16	Standard	25000.00	455.4 / 165.2	3.64	3238305	NA	NA	NA	R	22474.103	89.90	erapamil	108.85	
Group001, Inj	njection 17	17	Blank	N/A	455.4 / 165.2	3.86	4491	NA	NA	NA		19.208	NA	verapamil	100.00	
Group001, In			Elenk	N/A		4.09	5638	NA		NA		27.175	NA	verapamil	105.27	1
	niection 19	19	Elank	N/A		4.31	1211	NA		NA		<0	NA	verapamil		
Group001, Inj													NA	verapamil		1.1
Group001, In Group001, In		20	Elank	NA	455.4 / 165.2	4.54	551	NA	NA	NA		<0	nin	Veraparte	103.46	11
Group001, In	njection 20	-		N/A	455.4 / 165.2	4.54	551	NA	NA	NA	C	~		Veraparte		-
Group001, In	njection 20	89.				454	551	NA	NA	NA		0	Ĵ	Veraparen	99.63	-
Group001, In III: EReg bration for 455	njection 20	89.				4.54	551	NA	NA	NA			Ĵ			,
Group001, In Bration for 455 3.2e6	njection 20	89.				434	551	NA	NA	NA					99.63 97.43	,
Group001, In Brage bration for 455 3.2e6 - 3.0e6 -	njection 20	89.				4.54	551	NA	NA	NA					99.63	,
Group001, In III: E Reg bration for 455 3.2e6 3.0e6 2.8e6	njection 20	89.				454	551	NA	NA	NA					99.63 97.43 91.83	1
Group001, In Brasion for 455 3.2e6 3.0e6 2.8e6 2.6e6	njection 20	89.				454	551	NA	NGA	NA					99.63 97.43	1
Group001, In bration for 455 3.2e6 2.8e6 2.6e6 2.4e6	njection 20	89.				454	551	NA	NGA	NA		a			99.63 97.43 91.83	1
Group001, In Bration for 450 3,246 2,846 2,646 2,246 2,246	njection 20	89.				4.54	551	NA	NGA	NA					99.63 97.43 91.83	1
Group001, In Brasion for 455 3.246 2.866 2.666 2.465 2.266 2.066	njection 20	89.				4.54		NA	NGA	NA					99.63 97.43 91.83	1
Group001, In Bration for 455 3.0x6 2.8x6 2.6x6 2.4x6 2.2x6 2.2x6 1.8x6 -	njection 20	89.				454	551	NA	NGA	NA					99.63 97.43 91.83	1
Group001, In The Reg brasion for 455 3.245 2.965 2.965 2.965 2.965 2.965 2.965 1.965 1.965 1.965	njection 20	89.				454	551	NA	NA	NA					99.63 97.43 91.83	1
Group001, In Bration for 455 3.0x6 2.8x6 2.6x6 2.4x6 2.2x6 2.2x6 1.8x6 -	njection 20	89.				454	851	NA	NA	NA					99.63 97.43 91.83	1
Group001, In thrasion for 455 3.045 2.865 2.665 2.665 2.665 2.665 1.865 1.865 1.665 1.665 1.465 1.245	njection 20	89.				154	551	NA	NA	NA					99.63 97.43 91.83	1
Group001, In thraston for 455 3.045 2.665 2.665 2.665 2.665 1.665 1.665 1.465	njection 20	89.				154	551	NA	NA	NA		0			99.63 97.43 91.83	1
Group001, In thrasion for 455 3.045 2.865 2.665 2.665 2.665 2.665 1.865 1.865 1.665 1.665 1.465 1.245	njection 20	89.				154	551	NA	NA	NA		0			99.63 97.43 91.83	1
Group001, In The Registration for 450 3.246 2.966 2.966 2.966 2.966 1.96	njection 20	89.				154	561	NA NA		NA		0			99.63 97.43 91.83	1
Group001, In The Reg bration for 455 3.045 2.045 2.045 2.045 2.045 1.04	njection 20	89.				154	551	NA				0			99.63 97.43 91.83	1
Group001, In The Press Brasson for 450 3.245 3.245 2.865 2.265 2.245 2.245 2.245 1.865 1.865 1.665 1.665 6.045 6.045 5.	njection 20	89.					551	NA	•			0			99.63 97.43 91.83	
Group001, In Terration for 450 3.246 3.246 2.866 2.866 2.445 2.246 2.246 1.866 1.866 1.866 1.866 1.866 1.866 1.866 4.805 4.085 4.085 4.085	njection 20	19 Q. (378 x + 1724 5771					100 12000		1400 150		000 17000	1000 100		99.63 97.43 91.83	1




Leveraging Flexibility to Expedite Analysis


<u>Solution:</u> Maximize throughput and reproducibility via dual-stream analysis of 2 different analytes simultaneously

Stream 1 injects propranolol Stream 2 injects diclofenac







Dual-Stream Metabolic Stability (HLM)




Dual Stream Analysis: Data Deconvolution



Dual Stream Analysis: Data Deconvolution





Acknowledgements

Pfizer

Mary Piotrowski Hui Zhang Veronica Zelesky Jefry Shields Jianhua Liu Carrie Funk John Janiszewski Matt Troutman Mark West Bo Feng

Sound Analytics

Wayne Lootsma Steve Ainley Will Schramm Kevin Shirey

Apricot Designs Jeremy Lawton

Bob Biagioni

AB SCIEX Tony Romanelli Joe Doktorski

24